Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 5/20 | 0.56 |
| ▸ | KDM4E | B2RXH2 | 8/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.51 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.48 |
| ▸ | HPGD | P15428 | 3/20 | 0.46 |
| ▸ | MAPT | P10636 | 8/20 | 0.46 |
| ▸ | TP53 | P04637 | 2/20 | 0.45 |
| ▸ | THRB | P10828 | 1/20 | 0.45 |
| ▸ | FNTA | P49354 | 1/20 | 0.45 |
| ▸ | FNTB | P49356 | 1/20 | 0.45 |
| ▸ | MEN1 | O00255 | 4/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.45 |
| ▸ | HTT | P42858 | 2/20 | 0.45 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.45 |
| ▸ | RECQL | P46063 | 1/20 | 0.45 |
| ▸ | RAB9A | P51151 | 2/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12942054 | 0.85 | ADORA2A (0.48) | GAAKDM4EALDH1A1SMN1; SMN2HPGD | |
| SCHEMBL2705788 | 0.85 | KDM4E (0.56) | GAAKDM4EALDH1A1SMN1; SMN2MAPK1 | |
| SCHEMBL28928759 | 0.84 | ESR1 (0.49) | GAAKDM4EALDH1A1SMN1; SMN2MAPK1 | |
| SCHEMBL3612395 | 0.83 | MAPT (0.57) | KDM4EALDH1A1SMN1; SMN2MAPK1HPGD | |
| SCHEMBL1173463 | 0.83 | PRKCZ (0.54) | GAAKDM4EALDH1A1SMN1; SMN2MAPK1 | |
| SCHEMBL10222539 | 0.83 | ALDH1A1 (0.58) | KDM4EALDH1A1SMN1; SMN2MAPK1HPGD | |
| SCHEMBL5733736 | 0.82 | CDC7 (0.53) | ALDH1A1MAPK1HPGDMAPTMEN1 | |
| SCHEMBL694852 | 0.82 | ALDH1A1 (0.56) | GAAKDM4EALDH1A1SMN1; SMN2MAPK1 | |
| SCHEMBL12941873 | 0.82 | KDM4E (0.42) | GAAKDM4EALDH1A1SMN1; SMN2MAPK1 | |
| SCHEMBL18425631 | 0.82 | RAB9A (0.57) | GAAKDM4EALDH1A1SMN1; SMN2MAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3511319-B1 | INHIBITORS OF LYSINE SPECIFIC DEMETHYLASE-1 | CELGENE QUANTICEL RES INC (US) | 2023-05-03 | — | — | EP | disclosed |
| EP-3511319-B1 | INHIBITORS OF LYSINE SPECIFIC DEMETHYLASE-1 | CELGENE QUANTICEL RES INC (US) | 2023-05-03 | — | — | EP | disclosed |
| EP-3164380-B1 | INHIBITORS OF LYSINE SPECIFIC DEMETHYLASE-1 | CELGENE QUANTICEL RES INC (US) | 2022-02-09 | — | — | EP | disclosed |
| CN-108530424-B | Inhibitors of lysine-specific demethylase-1 | 赛尔基因昆蒂赛尔研究公司 | 2021-10-01 | — | — | CN | disclosed |
| EP-3511319-A1 | INHIBITORS OF LYSINE SPECIFIC DEMETHYLASE-1 | Celgene Quanticel Research, Inc. (US) | 2019-07-17 | — | — | EP | disclosed |
| EP-3511319-A1 | INHIBITORS OF LYSINE SPECIFIC DEMETHYLASE-1 | Celgene Quanticel Research, Inc. (US) | 2019-07-17 | — | — | EP | disclosed |
| US-20190002456-A1 | INHIBITORS OF LYSINE SPECIFIC DEMETHYLASE-1 | CELGENE QUANTICEL RES INC (US) | 2019-01-03 | — | — | US | disclosed |
| US-20190002456-A1 | INHIBITORS OF LYSINE SPECIFIC DEMETHYLASE-1 | CELGENE QUANTICEL RES INC (US) | 2019-01-03 | — | — | US | disclosed |
| US-10100046-B2 | Inhibitors of lysine specific demethylase-1 | CELGENE QUANTICEL RESEARCH, INC. (US) | 2018-10-16 | — | — | US | disclosed |
| US-20180127408-A1 | INHIBITORS OF LYSINE SPECIFIC DEMETHYLASE-1 | CELGENE QUANTICEL RES INC (US) | 2018-05-10 | — | — | US | disclosed |
| US-20180127408-A1 | INHIBITORS OF LYSINE SPECIFIC DEMETHYLASE-1 | CELGENE QUANTICEL RES INC (US) | 2018-05-10 | — | — | US | disclosed |
| US-9902719-B2 | Inhibitors of lysine specific demethylase-1 | CELGENE QUANTICEL RESEARCH, INC. (US) | 2018-02-27 | — | — | US | disclosed |
| US-9902719-B2 | Inhibitors of lysine specific demethylase-1 | CELGENE QUANTICEL RESEARCH, INC. (US) | 2018-02-27 | — | — | US | disclosed |
| US-20170129882-A1 | INHIBITORS OF LYSINE SPECIFIC DEMETHYLASE-1 | CELGENE QUANTICEL RESEARCH, INC. (US) | 2017-05-11 | — | — | US | disclosed |
| US-20170129882-A1 | INHIBITORS OF LYSINE SPECIFIC DEMETHYLASE-1 | CELGENE QUANTICEL RESEARCH, INC. (US) | 2017-05-11 | — | — | US | disclosed |
| EP-3164380-A1 | INHIBITORS OF LYSINE SPECIFIC DEMETHYLASE-1 | Celgene Quanticel Research, Inc. (US) | 2017-05-10 | — | — | EP | disclosed |
| WO-2016003917-A1 | INHIBITORS OF LYSINE SPECIFIC DEMETHYLASE-1 | Quanticel Pharmaceuticals, Inc. (US) | 2016-01-07 | — | — | WO | disclosed |
| WO-2016003917-A1 | INHIBITORS OF LYSINE SPECIFIC DEMETHYLASE-1 | Quanticel Pharmaceuticals, Inc. (US) | 2016-01-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170129882-A1 | INHIBITORS OF LYSINE SPECIFIC DEMETHYLASE-1 | KDM1B, KDM1A, KDM3A | GAA 1295/4885KDM4E 16/4885ALDH1A1 235/4885 |
| US-20180127408-A1 | INHIBITORS OF LYSINE SPECIFIC DEMETHYLASE-1 | KDM1B, KDM1A, KDM3A | GAA 1295/4885KDM4E 16/4885ALDH1A1 235/4885 |
| US-10100046-B2 | Inhibitors of lysine specific demethylase-1 | KDM1B, KDM1A, KDM3A | GAA 1295/4885KDM4E 16/4885ALDH1A1 235/4885 |
| US-20190002456-A1 | INHIBITORS OF LYSINE SPECIFIC DEMETHYLASE-1 | KDM1B, KDM1A, KDM3A | GAA 1295/4885KDM4E 16/4885ALDH1A1 235/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.